Biotherapeutics News and Research

RSS

FUJIFILM Irvine Scientific Expands BalanCD CHO Media Platform Portfolio for Bioprocessing

Chemically defined media optimized for growth and productivity of CHO cells in perfusion and batch and fed-batch bioprocesses.

From FUJIFILM Irvine Scientific 11 Apr 2023

Snapping at new biotech breakthroughs with Gator Pro

In this interview, we speak to Subodh Nimkar, Marketing Director at Gator Bio, about their latest technology, Gator Pro which allows for fast, reliable, and high-quality data.

From Gator Bio, Inc. 21 Mar 2023

Realizing the Importance of Medical Electronic Devices

News Medical speaks to Brian Anthony, co-director of MIT’s Medical Electronic Device Realization Center, about the effect machine learning and sensor technologies have had on medical device engineering, as well as the Bioprocess Data Analytics and Machine Learning course he co-leads at MIT.

From Massachusetts Institute of Technology (MIT) 20 Mar 2023

USC researchers identify two promising avenues for developing new ALS treatments

Each year in the U.S., 5,000 patients receive a diagnosis of ALS, an incurable neurodegenerative disease that will likely kill them within two to five years.

7 Feb 2023

InDevR raises $9 million in series B financing and partners with bioMérieux

New partnerships will drive the commercial expansion of InDevR’s game-changing solutions for vaccines and biotherapeutics.

20 Jan 2023

Researchers create the first 'living medicine' to treat drug-resistant lung infections

Researchers have designed the first 'living medicine' to treat lung infections. The treatment targets Pseudomonas aeruginosa, a type of bacteria which is naturally resistant to many types of antibiotics and is a common source of infections in hospitals.

19 Jan 2023

Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery

Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma’s CMC (chemistry, manufacturing and controls) development.

From Vector BioPharma 10 Jan 2023

Brief roundup of research done by experts at UCLA Health

Below is a brief roundup of news and story ideas from the experts at UCLA Health.

21 Dec 2022

Does breast milk influence infants' intestinal microbiota?

A large number of health-related benefits of probiotics have led to the development of a new discipline called probiogenomics, which focuses on the molecular mechanisms of probiotic activities. According to the US Food and Drug Administration (FDA), the next-generation probiotics satisfy the scope of "live biotherapeutic products" (LBPs), which could be used to develop effective therapeutics for various diseases.

28 Nov 2022

New microfluidic Organ Chip platform replicates the human vaginal tissue microenvironment

The human microbiome has been a hot topic over the last decade, with research pointing to disrupted bacterial communities as culprits for a host of maladies including irritable bowel syndrome, eczema, and autoimmune diseases.

28 Nov 2022

Discovery could lead to new mantle cell lymphoma drugs

A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically slows the growth of this lymphoma in preclinical tests, according to a study from Weill Cornell Medicine researchers.

22 Nov 2022

New lab technique could spark a 'paradigm shift' in testing protein-based drugs

New Jersey Institute of Technology researchers have unveiled a new lab technique they say represents a "paradigm shift" in how pharmaceutical laboratories test and produce new protein-based drugs, such as therapeutic monoclonal antibodies being developed to treat a variety of diseases, from cancers to infectious diseases.

27 Sep 2022

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported at the ESMO Congress 2022 from the phase 3 M14TIL trial.

12 Sep 2022

Mechanistic insights into engineered ACE2 receptor traps

Researchers determined the cryo-electron microscopic (cryo-EM) structures of engineered angiotensin-converting enzyme 2 (ACE2) receptor traps.

12 Aug 2022

Using CRISPR to Lift the Lid on Probiotics

In this interview, we speak to Echo Pan, a Ph.D. student from North Carolina State University about her latest research that used CRISPR to uncover more on probiotics.

26 Jul 2022

New technology may enable rapid diagnosis of Ebola virus

A new tool can quickly and reliably identify the presence of Ebola virus in blood samples, according to a study by researchers at Washington University School of Medicine in St. Louis and colleagues at other institutions.

8 Jun 2022

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

From Bruker Cellular Analysis 6 Jun 2022

UNC-Chapel Hill secures $65 million NIH grant for establishing Antiviral Drug Discovery Center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health awarded the UNC Gillings School of Global Public Health a $65 million grant establishing an Antiviral Drug Discovery Center to develop oral antivirals that can combat pandemic-level viruses like COVID-19.

20 May 2022

NIH awards $577 million to establish AViDD Centers for Pathogens of Pandemic Concern

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

18 May 2022

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin did not significantly reduce patients' risk of organ failure, kidney problems, or death compared with placebo, although numerically fewer participants treated with dapagliflozin experienced these outcomes. The findings are published in CJASN.

29 Apr 2022